The Clinical Observation Of Yiqiqiangxin Decoction In Treatment Of Chronic Heart Failure

Objective: To observe the clinical efficacy and safety of Yiqiqiangxin Decoction intreatment of qi deficiency and blood stasis syndrome of chronic heart failure patient.Methods: according to the cases included in the standard, select60patients caused bychronic cheart failure, coronary heart disease were randomly divided into treatment groupand control group.30cases of control group given conventional western medicinetreatment; Treatment group30cases, on the basis of conventional western medicinetherapy plus yiqiqiangxin Decoction,4weeks for a period of treatment, we assessed theclinical curative effect. Observed before and after treatment in patients with cardiacfunction classification (NYHA classification), Lee’s heart failure classification,6minuteswalking distance, TCM syndrome, heart colour to exceed, ejection fraction, pro-theBNP’s change and the improvement of the quality of life, and before the treatment, blood,urine, stool routine, after comparing the examination such as liver and kidney function, soas to evaluate its efficacy and safety.Results:4weeks after treatment, clinical researchshows that:1. Heart failure (Lee’s): curative effect exists in the two groups was verysignificant difference (P <0.01), the treatment group is better than the control group.2.Heart function efficacy: comparison between the two groups (P>0.05there was nosignificant difference, the treatment group compared with control group no significantdifference.3. The curative effect in six-minute walk-test aspects: two groups existsignificant difference (P <0.05), the treatment group is better than the control group.4.Syndromes curative effect: two groups have significant difference (P <0.05), the treatmentgroup is better than the control group.5. Improve cardiac ejection fraction: the treatmentgroup after treatment compared with before treatment, EF value was very significant (P <0.01); The control group after treatment compared with before treatment EF value has avery significant increase (P <0.01). The comparison between groups after treatment, EF value has no significant difference (P>0.05).6. Two groups of NT-proBNP horizontalcomparison: the treatment group after treatment compared with before treatment, NT-proBNP have a significantly lower (P <0.01); The control group after treatment comparedwith before treatment NT-proBNP have a significantly lower (P <0.01). Comparisonbetween groups after treatment, the NT-proBNP have significant difference (P <0.05),the treatment group is better than the control group.7. Two sets of the quality of livingsurvey of Minnesota integral contrast: the treatment group after treatment compared withbefore treatment, integral have significantly lower (P <0.05); The control group aftertreatment compared with before treatment integral have significantly lower (P <0.05).Integral is compared between treatment group with significant difference (P <0.05). Allthe patients before and after medication for blood, urine, stool routine, liver and kidneyfunction safety indexes such as testing, the indicators before and after treatment had noobvious difference between experimental drug use is safe.